Anti-IgE Treatment for Disorders Other Than Asthma
Immunoglobulin E (IgE) plays a key role in the pathogenesis of many allergic diseases. Thus, IgE-mediated immunologic pathways are an attractive target for intervention in allergic diseases. Omalizumab is a recombinant humanized monoclonal antibody that binds IgE and has been used treat allergic ast...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2017-09-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/article/10.3389/fmed.2017.00152/full |
| _version_ | 1819179265414922240 |
|---|---|
| author | Jeffrey Stokes |
| author_facet | Jeffrey Stokes |
| author_sort | Jeffrey Stokes |
| collection | DOAJ |
| description | Immunoglobulin E (IgE) plays a key role in the pathogenesis of many allergic diseases. Thus, IgE-mediated immunologic pathways are an attractive target for intervention in allergic diseases. Omalizumab is a recombinant humanized monoclonal antibody that binds IgE and has been used treat allergic asthma for over a decade. Currently, omalizumab is approved for the treatment of both allergic asthma and chronic spontaneous urticaria. Since IgE plays a critical role in other allergic diseases, anti-IgE therapy has been evaluated in other allergic diseases in small clinical trials and case reports. Omalizumab has demonstrated efficacy in treating allergic rhinitis, atopic dermatitis, physical urticarias, mast cell disorders, food allergy, and other allergic diseases. In addition, the use of omalizumab with conventional allergen immunotherapy improves both safety and effectiveness. |
| first_indexed | 2024-12-22T21:55:42Z |
| format | Article |
| id | doaj.art-185d78beefb048539c8b07a05bd3a4a5 |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-12-22T21:55:42Z |
| publishDate | 2017-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-185d78beefb048539c8b07a05bd3a4a52022-12-21T18:11:14ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2017-09-01410.3389/fmed.2017.00152267663Anti-IgE Treatment for Disorders Other Than AsthmaJeffrey Stokes0Division of Allergy, Immunology and Pulmonary Medicine, Department of Pediatrics, Washington University in St. Louis School of Medicine, St. Louis, MO, United StatesImmunoglobulin E (IgE) plays a key role in the pathogenesis of many allergic diseases. Thus, IgE-mediated immunologic pathways are an attractive target for intervention in allergic diseases. Omalizumab is a recombinant humanized monoclonal antibody that binds IgE and has been used treat allergic asthma for over a decade. Currently, omalizumab is approved for the treatment of both allergic asthma and chronic spontaneous urticaria. Since IgE plays a critical role in other allergic diseases, anti-IgE therapy has been evaluated in other allergic diseases in small clinical trials and case reports. Omalizumab has demonstrated efficacy in treating allergic rhinitis, atopic dermatitis, physical urticarias, mast cell disorders, food allergy, and other allergic diseases. In addition, the use of omalizumab with conventional allergen immunotherapy improves both safety and effectiveness.http://journal.frontiersin.org/article/10.3389/fmed.2017.00152/fullomalizumaburticariaasthmaimmunotherapyallergy |
| spellingShingle | Jeffrey Stokes Anti-IgE Treatment for Disorders Other Than Asthma Frontiers in Medicine omalizumab urticaria asthma immunotherapy allergy |
| title | Anti-IgE Treatment for Disorders Other Than Asthma |
| title_full | Anti-IgE Treatment for Disorders Other Than Asthma |
| title_fullStr | Anti-IgE Treatment for Disorders Other Than Asthma |
| title_full_unstemmed | Anti-IgE Treatment for Disorders Other Than Asthma |
| title_short | Anti-IgE Treatment for Disorders Other Than Asthma |
| title_sort | anti ige treatment for disorders other than asthma |
| topic | omalizumab urticaria asthma immunotherapy allergy |
| url | http://journal.frontiersin.org/article/10.3389/fmed.2017.00152/full |
| work_keys_str_mv | AT jeffreystokes antiigetreatmentfordisordersotherthanasthma |